Your browser doesn't support javascript.
loading
Molecular Testing of Lung Cancers
Journal of Pathology and Translational Medicine ; : 242-254, 2017.
Article in English | WPRIM | ID: wpr-38101
ABSTRACT
Targeted therapies guided by molecular diagnostics have become a standard treatment of lung cancer. Epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements are currently used as the best predictive biomarkers for EGFR tyrosine kinase inhibitors and ALK inhibitors, respectively. Besides EGFR and ALK, the list of druggable genetic alterations has been growing, including ROS1 rearrangements, RET rearrangements, and MET alterations. In this situation, pathologists should carefully manage clinical samples for molecular testing and should do their best to quickly and accurately identify patients who will benefit from precision therapeutics. Here, we grouped molecular biomarkers of lung cancers into three categories—mutations, gene rearrangements, and amplifications—and propose expanded guidelines on molecular testing of lung cancers.
Subject(s)

Full text: Available Index: WPRIM (Western Pacific) Main subject: Phosphotransferases / Protein-Tyrosine Kinases / Biomarkers / Gene Rearrangement / Precision Medicine / Pathology, Molecular / ErbB Receptors / Lung / Lung Neoplasms / Lymphoma Type of study: Diagnostic study / Practice guideline / Prognostic study Limits: Humans Language: English Journal: Journal of Pathology and Translational Medicine Year: 2017 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Phosphotransferases / Protein-Tyrosine Kinases / Biomarkers / Gene Rearrangement / Precision Medicine / Pathology, Molecular / ErbB Receptors / Lung / Lung Neoplasms / Lymphoma Type of study: Diagnostic study / Practice guideline / Prognostic study Limits: Humans Language: English Journal: Journal of Pathology and Translational Medicine Year: 2017 Type: Article